VJHemOnc is committed to improving our service to you

ASH 2019 | PBCAR0191 allo-CAR-T for ALL and NHL: preliminary findings

VJHemOnc is committed to improving our service to you

Bijal Shah

Bijal Shah, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the initial findings of the phase 1 trial (NCT03666000) of PBCAR0191, an anti-CD19 allogeneic CAR T-cell product designed to reduce the risk of graft-versus-host disease (GvHD), which is a limitation of allogeneic products, in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Additionally, Dr Shah mentions the next steps in the dose-escalation study of safety of PBCAR0191. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter